0 21

Cited 0 times in

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04

 Jin Seok Ahn  ;  Yong Chan Ahn  ;  Joo-Hang Kim  ;  Chang Geol Lee  ;  Eun Kyung Cho  ;  Kyu Chan Lee  ;  Ming Chen  ;  Dong-Wan Kim  ;  Hoon-Kyo Kim  ;  Young Joo Min  ;  Jin-Hyoung Kang  ;  Jin-Hyuck Choi  ;  Sang-We Kim  ;  Guangying Zhu  ;  Yi-Long Wu  ;  Sung Rok Kim  ;  Kyung Hee Lee  ;  Hong Suk Song  ;  Yoon-La Choi  ;  Jong-Mu Sun  ;  Sin-Ho Jung  ;  Myung-Ju Ahn  ;  Keunchil Park 
 JOURNAL OF CLINICAL ONCOLOGY, Vol.33(24) : 2660-2666, 2015-08 
Journal Title
Issue Date
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols / therapeutic use* ; Carcinoma, Non-Small-Cell Lung / drug therapy* ; Carcinoma, Non-Small-Cell Lung / pathology ; Carcinoma, Non-Small-Cell Lung / radiotherapy ; Chemoradiotherapy ; Cisplatin / administration & dosage ; Docetaxel ; Female ; Humans ; Lung Neoplasms / drug therapy* ; Lung Neoplasms / pathology ; Lung Neoplasms / radiotherapy ; Male ; Middle Aged ; Neoplasm Staging ; Taxoids / administration & dosage
Purpose: To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally advanced non-small-cell lung cancer (LA-NSCLC). Patient and methods: Patients were randomly assigned to either CCRT alone (observation arm) or CCRT followed by CC (consolidation arm). CCRT with docetaxel (20 mg/m(2)) and cisplatin (20 mg/m(2)) was administered every week for 6 weeks with a total dose of 66 Gy of thoracic radiotherapy in 33 fractions. In the consolidation arm, patients were further treated with three cycles of DP (35 mg/m(2) each on days 1 and 8, every 3 weeks). The primary end point was 40% improvement in progression-free survival (PFS) compared with observation. Results: From October 2005 to April 2011, 437 patients were randomly assigned. Seventeen patients did not start CCRT as a result of consent withdrawal or ineligibility reasons after random assignment, leaving 420 patients for this analysis (n = 211 for observation; n = 209 for consolidation). Patient characteristics were similar in both arms. In the consolidation arm, 143 patients (68%) received CC, of whom 88 (62%) completed three planned cycles. The median PFS was 8.1 months in the observation arm and 9.1 months in the consolidation arm (hazard ratio, 0.91; 95% CI, 0.73 to 1.12; P = .36). Median overall survival times were 20.6 and 21.8 months in the observation and consolidation arms, respectively (HR, 0.91; 95% CI, 0.72 to 1.25; P = .44). Conclusion: CC with DP after CCRT with weekly DP in LA-NSCLC failed to further prolong PFS. CCRT alone should remain the standard of care. Trial registration: ClinicalTrials.gov NCT00326378.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Lee, Chang Geol(이창걸) ORCID logo https://orcid.org/0000-0002-8702-881X
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.